{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:11:48Z","timestamp":1791587508151,"version":"4.3.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":418,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.cmi.2022.10.018","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T13:16:13Z","timestamp":1666098973000},"page":"320-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"title":["Antibiotic heteroresistance in ESKAPE pathogens, from bench to bedside"],"prefix":"10.1016","volume":"29","author":[{"given":"M\u00e9lanie","family":"Roch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego O.","family":"Andrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2022.10.018_bib1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.10.018_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1128\/CMR.00058-14","article-title":"Antimicrobial heteroresistance: an emerging field in need of clarity","volume":"28","author":"El-Halfawy","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2022.10.018_bib3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41579-019-0218-1","article-title":"Mechanisms and clinical relevance of bacterial heteroresistance","volume":"17","author":"Andersson","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cmi.2022.10.018_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007726","article-title":"Heteroresistance: a cause of unexplained antibiotic treatment failure?","volume":"15","author":"Band","year":"2019","journal-title":"PLOS Pathog"},{"key":"10.1016\/j.cmi.2022.10.018_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.molcel.2019.09.028","article-title":"Bacterial heterogeneity and antibiotic survival: understanding and combatting persistence and heteroresistance","volume":"76","author":"Dewachter","year":"2019","journal-title":"Mol Cell"},{"key":"10.1016\/j.cmi.2022.10.018_bib6","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/s41564-019-0480-z","article-title":"Antibiotic combinations that exploit heteroresistance to multiple drugs effectively control infection","volume":"4","author":"Band","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.cmi.2022.10.018_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s42003-021-02052-x","article-title":"The highly dynamic nature of bacterial heteroresistance impairs its clinical detection","volume":"4","author":"Pereira","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.cmi.2022.10.018_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106065","article-title":"Colistin heteroresistance in Acinetobacter spp: systematic review and meta-analysis of the prevalence and discussion of the mechanisms and potential therapeutic implications","volume":"56","author":"Karakonstantis","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2022.10.018_bib9","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/jac\/dks084","article-title":"Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies","volume":"67","author":"Cai","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2022.10.018_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-1-4939-9118-1_4","article-title":"Methods to evaluate colistin heteroresistance in Acinetobacter baumannii","volume":"1946","author":"Sherman","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.cmi.2022.10.018_bib11","series-title":"The EUCAST guideline on detection of resistance mechanisms v 2.0","year":"2017"},{"key":"10.1016\/j.cmi.2022.10.018_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02881-20","article-title":"Colistin heteroresistance is largely undetected among carbapenem-resistant Enterobacterales in the United States","volume":"12","author":"Band","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.cmi.2022.10.018_bib13","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1128\/AAC.02470-13","article-title":"\u2018Slow VISA,\u2019 a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3","volume":"58","author":"Saito","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.10.018_bib14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jac\/47.4.399","article-title":"A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital","volume":"47","author":"Wootton","year":"2001","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2022.10.018_bib15","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1128\/JCM.43.5.2494-2496.2005","article-title":"Unstable vancomycin heteroresistance is common among clinical isolates of methiciliin-resistant Staphylococcus aureus","volume":"43","author":"Plipat","year":"2005","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2022.10.018_bib16","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1128\/JCM.00599-15","article-title":"Effects of frozen storage on detection of intermediate vancomycin susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus blood isolates","volume":"53","author":"Riederer","year":"2015","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2022.10.018_bib17","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/myc.12639","article-title":"Heteroresistance and fungi","volume":"60","author":"Ferreira","year":"2017","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2022.10.018_bib18","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1099\/jmm.0.05176-0","article-title":"What makes resistance to methicillin heterogeneous?","volume":"52","author":"Rohrer","year":"2003","journal-title":"J\u00a0Med Microbiol"},{"key":"10.1016\/j.cmi.2022.10.018_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/CMR.00042-09","article-title":"Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications","volume":"23","author":"Howden","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2022.10.018_bib20","article-title":"Systematic review and meta-analysis of the epidemiology of vancomycin-intermediate and heterogeneous vancomycin-intermediate Staphylococcus aureus isolates","volume":"10","author":"Zhang","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.cmi.2022.10.018_bib21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1128\/AAC.01133-10","article-title":"Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates","volume":"55","author":"van Hal","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.10.018_bib22","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/phar.1577","article-title":"Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus","volume":"35","author":"Gomes","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2022.10.018_bib23","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1128\/AAC.04490-14","article-title":"Vancomycin-variable enterococci can give rise to constitutive resistance during antibiotic therapy","volume":"59","author":"Thaker","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.10.018_bib24","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.3389\/fmicb.2019.02546","volume":"10","author":"Bai","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cmi.2022.10.018_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02097-19","article-title":"Omadacycline efficacy against Enterococcus faecalis isolated in China: in vitro activity, heteroresistance, and resistance mechanisms","volume":"64","author":"Lin","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.10.018_bib26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jgar.2020.11.019","article-title":"Colistin-heteroresistance in carbapenemase-producing Enterobacter species causing hospital-acquired infections among Egyptian patients","volume":"24","author":"Mashaly","year":"2021","journal-title":"J\u00a0Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2022.10.018_bib27","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/jac\/dkr007","article-title":"Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae","volume":"66","author":"Meletis","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2022.10.018_bib28","first-page":"1444","article-title":"Colistin heteroresistance in Klebsiella pneumoniae isolates and diverse mutations of PmrAB and PhoPQ in resistant subpopulations","volume":"8","author":"Cheong","year":"2019","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.cmi.2022.10.018_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/nmicrobiol.2016.53","article-title":"Antibiotic failure mediated by a resistant subpopulation in Enterobacter cloacae","volume":"1","author":"Band","year":"2016","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.cmi.2022.10.018_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02448-17","article-title":"Carbapenem-resistant Klebsiella pneumoniae exhibiting clinically undetected colistin heteroresistance leads to treatment failure in a murine model of infection","volume":"9","author":"Band","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.cmi.2022.10.018_bib31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.diagmicrobio.2017.10.006","article-title":"Emergence of polymyxin B resistance in a polymyxin B-susceptible KPC-producing Klebsiella pneumoniae causing bloodstream infection in a neutropenic patient during polymyxin B therapy","volume":"90","author":"Zavascki","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2022.10.018_bib32","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/jac\/dkab461","article-title":"Prevalence of colistin heteroresistance in carbapenem-resistant Pseudomonas aeruginosa and association with clinical outcomes in patients: an observational study","volume":"77","author":"Howard-Anderson","year":"2022","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2022.10.018_bib33","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.diagmicrobio.2009.05.019","article-title":"Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin","volume":"65","author":"Rodriguez","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2022.10.018_bib34","doi-asserted-by":"crossref","DOI":"10.5812\/jjm.12287","article-title":"Post neurosurgical meningitis due to colistin heteroresistant Acinetobacter baumannii","volume":"7","author":"Moosavian","year":"2014","journal-title":"Jundishapur J Microbiol"},{"key":"10.1016\/j.cmi.2022.10.018_bib35","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1128\/AAC.00103-06","article-title":"Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii","volume":"50","author":"Li","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.10.018_bib36","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2022.10.018_bib37","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America guidance on the treatment of AmpC beta-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.10.018_bib38","first-page":"1506","article-title":"Prevalence of the carbapenem-heteroresistant phenotype among ESBL-producing Escherichia coli and Klebsiella pneumoniae clinical isolates","volume":"75","author":"Tan","year":"2020","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2022.10.018_bib39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10096-017-3138-x","article-title":"Carbapenem-heteroresistance among isolates of the Enterobacter cloacae complex: is it a real concern?","volume":"37","author":"da Silva","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2022.10.018_bib40","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1128\/JCM.02134-09","article-title":"Characteristics of meropenem heteroresistance in Klebsiella pneumoniae carbapenemase (KPC)-producing clinical isolates of K. pneumoniae","volume":"48","author":"Pournaras","year":"2010","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2022.10.018_bib41","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1128\/JCM.01130-10","article-title":"Carbapenem heteroresistance in VIM-1-producing Klebsiella pneumoniae isolates belonging to the same clone: consequences for routine susceptibility testing","volume":"48","author":"Tato","year":"2010","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2022.10.018_bib42","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.2147\/IDR.S340652","article-title":"Impact of carbapenem heteroresistance among multidrug-resistant ESBL\/AmpC-producing Klebsiella pneumoniae clinical isolates on antibiotic treatment in experimentally infected mice","volume":"14","author":"Xiong","year":"2021","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.cmi.2022.10.018_bib43","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1099\/jmm.0.46816-0","article-title":"Characterization of clinical isolates of Pseudomonas aeruginosa heterogeneously resistant to carbapenems","volume":"56","author":"Pournaras","year":"2007","journal-title":"J\u00a0Med Microbiol"},{"key":"10.1016\/j.cmi.2022.10.018_bib44","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijantimicag.2017.10.014","article-title":"Heteroresistance to carbapenems in invasive Pseudomonas aeruginosa infections","volume":"51","author":"He","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2022.10.018_bib45","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ijantimicag.2012.01.015","article-title":"Prevalence and analysis of microbiological factors associated with phenotypic heterogeneous resistance to carbapenems in Acinetobacter baumannii","volume":"39","author":"Fern\u00e1ndez Cuenca","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2022.10.018_bib46","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1128\/JCM.00959-09","article-title":"Heteroresistance to meropenem in carbapenem-susceptible Acinetobacter baumannii","volume":"47","author":"Ikonomidis","year":"2009","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2022.10.018_bib47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1590\/S0036-46652009000200010","article-title":"Indications of carbapenem resistance evolution through heteroresistance as an intermediate stage in Acinetobacter baumannii after carbapenem administration","volume":"51","author":"Superti","year":"2009","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"10.1016\/j.cmi.2022.10.018_bib48","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01968-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.10.018_bib49","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2022.10.018_bib50","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(21)00194-8","article-title":"Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens","volume":"21","author":"Choby","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2022.10.018_bib51","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1473-3099(21)00328-5","article-title":"Placing in-vitro heteroresistance in the context of clinical results","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2022.10.018_bib52","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1080\/22221751.2019.1601031","article-title":"Detection and characterization of tigecycline heteroresistance in E. cloacae: clinical and microbiological findings","volume":"8","author":"Liu","year":"2019","journal-title":"Emerg Microbe. Infect"},{"key":"10.1016\/j.cmi.2022.10.018_bib53","article-title":"Characterization of tigecycline-heteroresistant Klebsiella pneumoniae clinical isolates from a Chinese tertiary care teaching hospital","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cmi.2022.10.018_bib54","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.01010-21","article-title":"Tigecycline heteroresistance and resistance mechanism in clinical isolates of Acinetobacter baumannii","volume":"9","author":"Jo","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2022.10.018_bib55","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jgar.2020.04.026","article-title":"Characterization of fosfomycin heteroresistance among multidrug-resistant Escherichia coli isolates from hospitalized patients in Rio de Janeiro, Brazil","volume":"22","author":"Campos","year":"2020","journal-title":"J\u00a0Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2022.10.018_bib56","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01982-19","article-title":"Oral fosfomycin efficacy with variable urinary exposures following single and multiple doses against Enterobacterales: the importance of heteroresistance for growth outcome","volume":"64","author":"Abbott","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.10.018_bib57","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/jac\/dkz519","article-title":"Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections","volume":"75","author":"Abbott","year":"2020","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2022.10.018_bib58","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jama.2018.3627","article-title":"Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial","volume":"319","author":"Huttner","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2022.10.018_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.682239","article-title":"Heteroresistance to amikacin in carbapenem-resistant Klebsiella pneumoniae strains","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cmi.2022.10.018_bib60","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00271-18","article-title":"Aminoglycoside heteroresistance in Acinetobacter baumannii AB5075","volume":"3","author":"Anderson","year":"2018","journal-title":"mSphere"},{"key":"10.1016\/j.cmi.2022.10.018_bib61","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1128\/JCM.02129-13","article-title":"Irreproducible and uninterpretable polymyxin B MICs for Enterobacter cloacae and Enterobacter aerogenes","volume":"51","author":"Landman","year":"2013","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2022.10.018_bib62","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1128\/AAC.02574-14","article-title":"Exposure of Staphylococcus aureus to subinhibitory concentrations of \u03b2-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus","volume":"58","author":"Roch","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.10.018_bib63","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/jac\/dkn009","article-title":"Potential for underdosing and emergence of resistance in Acinetobacter baumannii during treatment with colistin","volume":"61","author":"David","year":"2008","journal-title":"J\u00a0Antimicrob Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22005328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22005328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:33:07Z","timestamp":1761118387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X22005328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1198743X22005328"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2022.10.018","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibiotic heteroresistance in ESKAPE pathogens, from bench to bedside","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2022.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}